Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and <i>FLT3</i> internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

The 2-year probability of OS was 62.7% (95% CI: 52.2–73.2) after SCT from a sibling donor, 57.7% (95% CI: 46.3–69.1) after SCT from a 10/10 unrelated donor and 42.2% (95% CI: 17.4–67) after SCT from a 9/10 unrelated donor, respectively, but those differences did not reach statistical significance across groups ( P =0.27).

also in 111,027 other papers

In multivariate analysis, active disease at the time of SCT was significantly associated with increased NRM ( P =0.01), while unrelated donors showed a trend toward a higher NRM ( Table 3 , Figure 2A ).

also in 53,322 other papers